Tier 4 — mechanistic

The use of betaine in the treatment of elevated homocysteine

Amy Lawson-Yuen, Harvey L Levy
Molecular genetics and metabolism 2006 88(3):201-207

Bibliography

PubMed
PMID 16545978
DOI
10.1016/j.ymgme.2006.02.004
Funding
Indexed grant support: 1U22MC03959 — PHS HHS — United States; R01-HG02085 — NHGRI NIH HHS — United States; T32 GM7748 — NIGMS NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2006, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Reviews prescription betaine for elevated homocysteine and emphasizes methionine monitoring in susceptible patients.

Rare-disease treatment experience cannot be directly generalized to healthy users or cardiovascular event prevention.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • Reviews prescription betaine for elevated homocysteine and emphasizes methionine monitoring in susceptible patients.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • Rare-disease treatment experience cannot be directly generalized to healthy users or cardiovascular event prevention.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004
Tier 4
Choline and betaine in health and disease
Per Magne Ueland et al. · Journal of inherited metabolic disease · 2011

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology